Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in ACS patients undergoing an Ad Hoc PCI

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Clopidogrel; Ticagrelor; Ticlopidine

Criteria

Inclusion Criteria:

• Provision of signed and dated informed consent before initiation of any study-related procedures

• Male or female patients aged 18 years or older

• Documented acute coronary syndrome and troponin negative and undergoing Ad Hoc percutaneous coronary intervention (PCI)

• Females must be post menopausal or surgically sterile

• Taking aspirin as an anti-platelet medication

Exclusion Criteria:

• Use of any thienopyridine or ticagrelor within 7 days prior to randomization

• Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve)

• Contraindication that ticagrelor or clopidogrel should not be administered Patient requires dialysis

• History of intolerance or allergy to aspirin